Inhibition of BUB1 results in genomic instability and anchorage-independent growth of normal human fibroblasts

Antonio Musio, Cristina Montagna, Desirée Zambroni, Esterina Indino, Ottavia Barbieri, Lorenzo Citti, Anna Villa, Thomas Ried, Paolo Vezzoni

Research output: Contribution to journalArticle

Abstract

The relative contribution of aneuploidy and gene mutations to human tumorigenesis is not yet known. Studies in mice have demonstrated that even single point mutations in oncogenes and tumor suppressor genes can dramatically increase tumor frequency. However, models to evaluate the definitive role of aneuploidy and genomic instability are not yet available. Human fibroblast cells have long been used as a tool for investigating proliferation, senescence, immortalization, and tumorigenesis, all processes that are strongly interrelated. We have now used antisense and ribozyme-mediated temporary inhibition of BUB1 to study the consequences of mitotic checkpoint failure on the development of aneuploidy. The analysis of cell colonies selected by soft agar growth showed evidence of chromosome instability and delayed senescence, without being tumorigenic in nude mice. Our data suggest that chromosomal instability and aneuploidy are early changes that precede tumorigenicity in the multistep process leading to neoplastic transformation.

Original languageEnglish
Pages (from-to)2855-2863
Number of pages9
JournalCancer Research
Volume63
Issue number11
Publication statusPublished - Jun 1 2003

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Inhibition of BUB1 results in genomic instability and anchorage-independent growth of normal human fibroblasts'. Together they form a unique fingerprint.

  • Cite this

    Musio, A., Montagna, C., Zambroni, D., Indino, E., Barbieri, O., Citti, L., Villa, A., Ried, T., & Vezzoni, P. (2003). Inhibition of BUB1 results in genomic instability and anchorage-independent growth of normal human fibroblasts. Cancer Research, 63(11), 2855-2863.